Nov. 14 at 7:01 PM
$MLTX MLTX at
$215 a share is a 'no-brainer'
SLK is now proving to be Best in Class Safety, Best in Class Efficacy, Best in Class Convenience and Best in Class. Compliance.
SLK hits on all S. E. C. C.
In the summer of 2026, MLTX will have overwhelming evidence and the scientific community anxiously awaiting their drug launch.
With just 71 million shares outstanding, far lower than any biopharma company at this stage of development, the
$15 billion dollar price tag for a NDA & BLA ready company is approximately
$215 per share.
$15 billion for MLTX in August of 2026 is not only reasonable, it's actually undervalued.
Last June Merck offered
$4 billion and MLTX had not even dosed the first patient in any Phase 3 trials. Other indications were also preliminary.
There is a huge disconnection between the scientific investors and the non-scientific investors.
Big Pharma price on science.. not charts when doing a BuyOut.
Remember this!
